Kymera Therapeutics (KYMR) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.32

Estimate

-$1.27

Surprise

-4.2%

Score today

4.9/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Kymera Therapeutics (KYMR) reported a wider loss than forecast — adjusted EPS of -$1.32 against the -$1.27 estimate (a 4.2% shortfall).

• Kymera Therapeutics Reports Third Quarter 2026 Financial Results and Positive KT-579 Phase 1 Data — fiscal.ai, 2026-10-29
• Kymera Therapeutics Q3 EPS $(1.32) Misses $(1.27) Estimate — benzinga, 2026-10-29
• Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results — fiscal.ai, 2026-10-28

TrendMatrix currently rates KYMR Sell at 4.9/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's -4.2% surprise compares with a +0.4% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$122.60

Price target

$125.84

Stop

$114.02

Upside to target

+2.6%

Reward-to-risk

0.2:1

Model outputs from TrendMatrix’s engine as of 2026-10-30 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$10.19B

P/E (fwd)

-24.1

52-week range

$55.66–$130.05

Off 52-week high

5.7%

RSI (14)

65

Volume vs avg

1.26×

Score today

4.9/10